Mezquita, L, Preeshagul, I, Auclin, E, Saravia, D, Hendriks, L, Rizvi, H, Park, W, Nadal, E, Martin-Romano, P, Ruffinelli, JC, Ponce, S, Audigier-Valette, C, Carnio, S, Blanc-Durand, F, Bironzo, P, Tabbo, F, Reale, ML, Novello, S, Hellmann, MD, Sawan, P, Girshman, J, Plodkowski, AJ, Zalcman, G, Majem, M, Charrier, M, Naigeon, M, Rossoni, C, Mariniello, A, Paz-Ares, L, Dingemans, AM, Planchard, D, Cozic, N, Cassard, L, Lopes, G, Chaput, N, Arbour, K, Besse, B. Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics. EUROPEAN JOURNAL OF CANCER. 2021; 151DOI:10.1016/j.ejca.2021.03.011. PMID:34022698. IF:10.002(Q1/2D).

Alvarez-Mancenido, F, Jimenez-Fonseca, P, Carmona-Bayonas, A, Arrazubi, V, Hernandez, R, Cano, JM, Custodio, A, Pijaume, CP, Aguado, G, Lago, NM, Canovas, MS, Lavin, DC, Visa, L, Martinez-Torron, A, Arias-Martinez, A, Lopez, F, Limon, ML, Tocino, RV, Montes, AF, Alsina, M, Pimentel, P, Reguera, P, Carnicero, AM, Ramchandani, A, Granja, M, Azkarate, A, Richard, MM, Serra, O, Perez, CH, Hurtado, A, Gil-Negrete, A, Sauri, T, del Burgo, PM, Gallego, J. Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry. Gastric Cancer. 2021; 24(4)DOI:10.1007/s10120-021-01169-6. PMID:33651195. IF:7.701(Q1/2D).

Laza-Briviesca, R, Cruz-Bermudez, A, Nadal, E, Insa, A, Garcia-Campelo, MD, Huidobro, G, Domine, M, Majem, M, Rodriguez-Abreu, D, Martinez-Marti, A, Carpeno, JD, Cobo, M, Vivanco, GL, Del Barco, E, Caro, RB, Vinolas, N, Aranda, IB, Viteri, S, Massuti, B, Casarrubios, M, Sierra-Rodero, B, Tarin, C, Garcia-Grande, A, Haymaker, C, Wistuba, II, Romero, A, Franco, F, Provencio, M. Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial. Clinical and Translational Medicine. 2021; 11(7)DOI:10.1002/ctm2.491. PMID:34323406. IF:8.554(Q1/2D).

Atenza, CZ, Anguera, G, Melia, MR, De Lamo, LA, Sullivan, I, Joaquin, AB, Lopez, JS, Ortiz, MA, Mulet, M, Vidal, S, Majem, M. The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents. CANCER IMMUNOLOGY IMMUNOTHERAPY. 2022; 71(8)DOI:10.1007/s00262-021-03107-y. PMID:34984538. IF:5.800(Q1/3D).

Arriola, E, Gonzalez-Cao, M, Domine, M, De Castro, J, Cobo, M, Bernabe, R, Navarro, A, Sullivan, I, Trigo, JM, Mosquera, J, Crama, L, Isla, D. Addition of Immune Checkpoint Inhibitors to Chemotherapy vs Chemotherapy Alone as First-Line Treatment in Extensive-Stage Small-Cell Lung Carcinoma: A Systematic Review and Meta-Analysis. Oncology And Therapy. 2022; 10(1)DOI:10.1007/s40487-021-00182-0. PMID:35032007. IF:(Q/D).

Remon, J, Bernabe, R, Diz, P, Felip, E, Gonzalez-Larriba, JL, Lazaro, M, Mielgo-Rubio, X, Sanchez, A, Sullivan, I, Massutti, B. SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021). Clinical & Translational Oncology. 2022; 24(4)DOI:10.1007/s12094-022-02788-w. PMID:35122634. IF:3.400(Q3/6D).